Solutions of appropriate concentrations of intralipid can be prepared that closely mimic the response of human or animal tissue to light at wavelengths in the red and infrared ranges where tissue is highly scattering but has a rather low absorption coefficient. Intralipid is also widely used in optical experiments to simulate the scattering properties of biological tissues. It was approved in the United States in 1972. In the United States, the Food and Drug Administration initially declined to approve the product due to prior experience with another fat emulsion. Intralipid was invented by the Swedish physician and nutrition researcher Arvid Wretlind, and was approved for clinical use in Sweden in 1962. An early product marketed in 1957 under the name Lipomul was briefly used in the United States but was subsequently withdrawn due to side effects. Intravenous lipid emulsions have been used experimentally since at least the 19th century. The possibility of lipid emulsions as an alternative drug delivery medium is under works. Sometimes etomidate (the vehicle for etomidate is propylene glycol) is supplied using a lipid emulsion as a vehicle. Propofol is dissolved in a lipid emulsion for intravenous use. They have subsequently been used off-label in the treatment of overdose from other fat-soluble medications. They have been effective in people unresponsive to the usual resuscitation methods. Lipid emulsions are effective in treating experimental models of severe cardiotoxicity from intravenous overdose of local anaesthetic drugs such as bupivacaine. These nutrients are combined with the intention of administering parenteral nutrition, where nutrients are delivered in an alternative pathway other than the gastrointestinal tract. The emulsion is used as a component of intravenous nutrition for people who are unable to get nutrition via an oral diet. Intralipid and other balanced lipid emulsions provide essential fatty acids, linoleic acid (LA), an omega-6 fatty acid, alpha-linolenic acid (ALA), an omega-3 fatty acid. The 30% concentration is not approved for direct intravenous infusion, but should be mixed with amino acids and dextrose as part of a total nutrient admixture. It is often referred to by the brand name of the most commonly used version, Intralipid, which is an emulsion containing soybean oil, egg phospholipids and glycerin, and is available in 10%, 20% and 30% concentrations. Lipid emulsion or fat emulsion refers to an emulsion of fat for human intravenous use, to administer nutrients to critically-ill patients that cannot consume food. For the more general topic of emulsified fats, see emulsion. Intralipid Intravenous lipid emulsion therapy Lipid emulsion Local anesthetic systemic toxicity.This article is about a medical product. The education of clinicians regarding the beneficial and varied roles of Intralipid therapy in different clinical settings is warranted, particularly in terms of the potential for Intralipid therapy to reverse the toxicities of non-local anesthetic drugs. These case reports included 49 separate drug overdose cases involving ten separate drug classes which were successfully reversed with Intralipid. To meet the objective of describing the growing number of indications for Intralipid therapy and any diverse effects and/or failures of Intralipid therapy in reversing multiple drug toxicities, we queried several Internet search engines with the key words "intravenous lipid emulsion therapy," "Intralipid," "lipid emulsion," and "local anesthetic systemic toxicity," resulting in the identification of 31 case reports for descriptive analysis. Some of these varied drug groups include antipsychotics, antidepressants, antiarrhythmics, and calcium channel blockers. Intravenous lipid emulsion (ILE Intralipid) therapy, a standard treatment in local anesthetic toxicity, has demonstrated therapeutic efficacies for a number of different drug class-mediated toxicities.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |